Martin Hoenigl

Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy - Intensive Care Medicine Background Invasive candidiasis (IC) remains one of the most challenging infections in critical care, contributing significantly to morbidity, prolonged organ support, and mortality among intensive ca...

link.springer.com/article/10.1...

rdcu.be/eL6ug

2025 #Candida #Guidelines by ECMM, ISHAM, ASM +

Summary recs here; full evidence, methods + pediatric guidance in appendix.

www.thelancet.com/journals/lan...

@olivercornely.bsky.social @martinhoenigl.bsky.social @anaalastruey.bsky.social @germhuntermd.bsky.social @fhagen.bsky.social

GALActIC Project – EU Collaboration Against IAPA | Consortium Meeting on Future Planning in Bilbao 🇪🇸

Galactic Europe: lnkd.in/d77xessA

@martinhoenigl.bsky.social
@simonfeys.bsky.social
@agocarvalho.bsky.social

✨📄 What about the untapped therapeutic potential of the immune response in invasive aspergillosis ? Here’s some rational, pre-clinical and clinical evidence. Huge thanks to our amazing 🌍 team!
🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social

🔥🗞️Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Groundbreaking work on a very promising new antifungal. Free access here:

authors.elsevier.com/c/1lHca5E-Uo...

🚨Our latest review in Thorax about the impact of climate change focusing on fungal pathogens in Europe 🌍

A truly enjoyable collaboration with Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social and @mbottery.bsky.social

thorax.bmj.com/content/earl...

Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge | NEJM Use of some antifungal pesticides may select for resistant fungi in the environment, which can then endanger human health. Coordinated regulatory processes in this area are important.

Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge

@grthompsonmd.bsky.social and Angel Desai

www.nejm.org/doi/full/10....

Health risks with environmental changes and mould exposure. Key impacts of flooding include increased precipitation, rising sea levels and land use changes, leading to indoor mould growth and health risks such as respiratory issues, asthma exacerbation and mould infections. Case studies highlight varying health outcomes from Hurricane Katrina and Rita (2005), Colorado Flood (2013) and Hurricane Harvey (2017).

Drivers of emerging fungal pathogens in a changing world. Climate change factors, such as rising temperatures and increasing resistance to fungicides, enhance fungal thermotolerance and drive the emergence of pathogens. Social determinants, including urbanisation, global travel and limited healthcare access, heighten human vulnerability to fungal infections. Other contributing factors, like environmental niches and unconfirmed environmental sources, further support the spread and persistence of fungal pathogens. These drivers contribute to the emergence of pathogens like Candida auris, Candida orthopsilosis and Cryptococcus deuterogatii.

Climate change and antifungal resistance: key mechanisms and pathogen examples. Climate change drives the development of antifungal resistance through mechanisms such as environmental pollution with fungicides, prolonged heat stress and increased mutation rates in fungi. These conditions promote genetic mutations, increased resistance to antifungal drugs and more challenging infections in humans and plants

Climate change: shifting boundaries of fungal disease in Europe and beyond

New review in Thorax

by @mbottery.bsky.social Sarah Sedik @germhuntermd.bsky.social @martinhoenigl.bsky.social @normanvanrhijn.bsky.social

thorax.bmj.com/content/thor... #MedSky #IDSky #PulmSky #ClimateSky #MedMycoSky

Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis Candida endophthalmitis and chorioretinitis are uncommon but potentially devastating complications of candidemia, associated with significant risks of vision loss and long-term morbidity. Effective ma...

Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis

Nate Permpalung, Sarah Sedik, Pete Pappas, @martinhoenigl.bsky.social, @drluiso.bsky.social in @cmijournal.bsky.social

www.clinicalmicrobiologyandinfection.com/article/S119...

Proud to present the progress of ECMM Candida IV study at #ISHAM2025

Still open for participation!

@martinhoenigl.bsky.social

Yesterday at ISHAM 2025, Danila Seidel explored how environmental extremes can spark fungal outbreaks 🌪️🌱
A powerful reminder of climate’s role in emerging mycoses. #ISHAM2025 #FungalOutbreaks #ClimateAndHealth #MedicalMycology

Did you know..75% of wine has significant levels of azole antifungals in it? (German wine anyway)

Potential consequences for driving resistance...

#IDSky #ISHAM

Happy to meet some wonderful colleagues & brilliant minds in Medical Mycology.
@martinhoenigl.bsky.social @germhuntermd.bsky.social at #ISHAM2025 It has been an amazing congress with enriching academic sessions, lovely food & great hospitality at such a captivating location @fozdoiguacu.bsky.social

Thrilled to see Dr. Jon Salmanton-García receive the GEMICOMED Young Researcher Award 2025! His impactful research on invasive fungal & viral infections in hematologic malignancies is shaping the future of mycology: www.journalofinfection.com/article/S016... #FungalResearch #Mycology

Its fake news

Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  - ECMM ECMM Candida IV Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida  Observation periods/Timeline Observation period: April 1st, 2024 – September 30th, ...

Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here: www.ecmm.info/working-grou...

@martinhoenigl.bsky.social

Sampling different types of grains at local markets in Namibia
starting our project

Fungal diversity of processed staple cereals from rural subsistence farming communities in Namibia

🙏🏻🙏🏻to colleagues from University of Namibia for hosting me

Honored to present today at ESCMID Global in Vienna: Ibrexafungerp salvage results from 233 patients in the FURI study — showing high success rates! 🔬💪 A promising new tool in the antifungal pipeline. #ESCMID2025 #FURIstudy #Ibrexafungerp #Antifungals #InfectiousDiseases

ECMM Candida IV Study is still open for participation

Global study on non-albicans candidemia

Requirements:

🔬Clinical data + isolates (no limit per site)
📅Apr 2024-Sep 2025
📦Ship isolates in one batch at study end
💰Case-based reimbursement available

@martinhoenigl.bsky.social

👉Participate in the ECMM Candida IV Study

🌍wide study on candidemia caused by non-albicans Candida

Requirement: clinical data & isolate (not req for C.auris)
Observation period: 04/2024 - 09/2025 Interested?

Email stella.wolfgruber@medunigraz.at

On April 1, 2025, our project officially started. A significant milestone that we have worked towards for a long time. Now, we look forward to taking the next steps together.

@martinhoenigl.bsky.social
@simonfeys.bsky.social
@agocarvalho.bsky.social

Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht Eine internationale Studie unter Beteiligung der Med Uni Graz erforscht bestimmte Biomarker im Zusammenhang mit Pilzinfektionen.

Projekt „GALActIC“ startet: Biomarker für Pilzinfektionen erforscht

www.medunigraz.at/news/detail/...

🔬💡 ICVS Researchers Join Innovative GALActIC Study to Combat IAPA!
Researchers of the I3D team are part of this European project, aiming to improve the identification and treatment of Influenza-associated Pulmonary Aspergillosis and enhance patient care! 🙌
More at: icvs.uminho.pt/icvs-researc...

Deadly fungi are becoming drug-resistant. A new compound could beat them A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice

A potentially new antifungal class:
Mandimycin, polyene-like but targeting phospholipids, rather than ergosterol.
✅activity against yeasts in vivo 🐁
With insights from @olivercornely.bsky.social
@martinhoenigl.bsky.social
& David Denning

www.science.org/content/arti...

Deadly fungi are becoming drug-resistant. A new compound could beat them A drug candidate with a new mechanism of action shows promise against several drug-resistant infections in mice

Deadly fungi are becoming drug-resistant. A new compound could beat them | Science | AAAS @kakape.bsky.social www.science.org/content/arti...

Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option Background Invasive mould infections (IMI) cause substantial morbidity and mortality in populations at risk. Novel treatment approaches are urgently needed. Targeting immune checkpoints may reverse ...

🔬 New research highlights a potential game-changer in treating invasive mould infections! 🦠 Patients show increased PD-1 expression, suggesting immune checkpoint inhibitors could help fight these deadly infections. More studies needed! 💡 onlinelibrary.wiley.com/doi/10.1111/... #Immunotherapy

New Medical Study Starting Soon 🔬

The logo was designed in collaboration with Galactic Partners, with professional support from Esra Sedik.

Follow us for more!

@martinhoenigl.bsky.social @agocarvalho.bsky.social
@simonfeys.bsky.social

AUC0-24/MIC for two different durations of antifungal treatment in ICU: 1-3 days vs 4-7 days, shown for various antifungals (and for caspofungin and anidulafungin shown separately for C albicans and C glabrata) PK/PD target-related exposures per occasion of the study antifungals prescribed for treatment. The shaded area represents the PK/PD target used in this study. For fluconazole, 15 data points are outside the y-axis limits (max AUC0-24/MIC value was 3250.3); ICU intensive care unit; AUC0-24 area under the plasma concentration-time curve from zero to 24 h; fAUC0-24 free AUC0-24; MIC minimum inhibitory concentration; Cmin minimum observed plasma concentration; Cmax maximum observed plasma concentration

Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter PK study for Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU)

J Roberts etc

TLDR: ++variable, need tailored approach w TDM

link.springer.com/article/10.1...

🌍 Fungal Care Gaps: Brazil vs. Europe 🇧🇷➡️🇪🇺

Fungal infections are a global challenge with uneven access to diagnostic and treatment. Europe has more labs, better tests, and antifungal access, while Brazil faces greater threats from Cryptococcus and Histoplasma.

journals.asm.org/doi/epub/10....

It’s out! A pleasure to work with @alukmd.bsky.social on the latest #fungal update of the ID Clinics of North America. I rembember saving money as a med student to buy them… #FullCircle #IDSky #MedSky